Recent Federal Circuit decisions are applying tighter limits to doctrine-of-equivalents arguments in pharma and biotech cases. This presentation explores where equivalence claims still succeed and how litigants are adjusting enforcement and design-around strategies accordingly.
Robin Ellis
Robin is a partner at Reddie & Grose, a full-service IP firm with offices in London, Munich and Cambridge.
Robin's practice focuses on multi-jurisdictional European litigation in the life science space. He regularly represents clients in opposition and appeal proceedings before the European Patent Office and has more recently advised clients on the fledgling SPC manufacturing waiver regulation.
Robin's 25 years in the profession has been split between roles in-house and private practice, which has given him a unique perspective on how to manage the multitude of IP issues now facing a pan-European product launch, including the introduction of the unified patent court.